The Link Between Manufacturing and Commercialization in Gene and Cell Therapies

May 15, 2019
Lev Gerlovin

,
Walter Colasante

Walter Colasante is a vice-president in Charles River Associates’ (CRA’s) Life Sciences Practice.

,
Pascale Diesel

Pascale Diesel is a vice-president in Charles River Associates’ (CRA’s) Life Sciences Practice.

Pharmaceutical Technology, Pharmaceutical Technology-05-15-2019, Volume 2019 eBook, Issue 1
Page Number: 30­–35

The highly customized nature of cell and gene therapy production means that manufacturing innovations for one therapy may not be easily transferable to others.

Now that the first cell and gene therapies have become commercial realities and more companies are involved in precision medicine research, different manufacturing platforms are being developed. However, as the authors write, developers need to consider the fundamental differences between these therapies and more traditional biopharmaceuticals to develop the right commercialization strategies.

Read this article in Pharmaceutical TechnologyBiologics and Sterile Drug Manufacturing 2019 eBook.

Article Details

Pharmaceutical Technology
eBook: Biologics and Sterile Drug Manufacturing 2019
May 2019
Pages: 30­–35

Citation

When referring to this article, please cite it as W. Colasante, P. Diesel, and L. Gerlovin, “The Link Between Manufacturing and Commercialization in Gene and Cell Therapies," Pharmaceutical Technology Biologics and Sterile Drug Manufacturing eBook (May 2019).